natgillin/translations-raw huggingface dataset:
Systemic exposure to FX:C at the Repeat PK visit (at least 6 months later) was equivalent to that at baseline, since repeat/baseline ratios for all PK parameters were within the range of 90% to 110%.
enakovredna tisti ob izhodišču, saj so bila razmerja ponovljeni/izhodiščni za vse parametre farmakokinetike v razponu od 90 % do 110 %.
Method of administration Intravenous use.
Intravenska uporaba
Coagadex should not be used as an antidote to the effects of direct oral anti-coagulants (DOACs) in patients who do not have factor X deficiency.
Teh protitrombotičnih zdravil se ne sme uporabljati pri bolnikih s pomanjkanjem faktorja X. Zdravila Coagadex ne smete uporabljati kot antidota za učinke neposrednih peroralnih zdravil za zaviranje strjevanja krvi pri bolnikih, ki nimajo pomanjkanja faktorja X.
Hypersensitivity reactions, allergic reactions, and anaphylaxis have not been reported in Coagadex clinical trials.
V kliničnih preskušanjih zdravila Coagadex niso poročali o preobčutljivostnih reakcijah, alergijskih reakcijah in anafilaksiji.
Talk to your doctor, pharmacist or nurse before using Coagadex:
Pred začetkom uporabe zdravila Coagadex se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
Signs of these may include skin rash (including hives), tingling, flushing, nausea, vomiting, headache, cough, wheezing, tightness of the chest, chills, fast heart rate, dizziness, lethargy, restlessness, swelling of the face, tightness of the throat, discomfort at the site of injection.
zbadanje, eritem), mrzlico, kašljem, omotico, povišano telesno temperaturo, zardevanjem, generalizirano urtikarijo, glavobolom, koprivnico, hipotenzijo, letargijo, bolečinami mišično-skeletnega sistema, navzeo, pruritusom, izpuščajem, nemirom, tahikardijo, tiščanjem v prsih, mravljinčenjem, bruhanjem, sopenjem.
• back pain
• bolečina v hrbtu
Prophylaxis of Bleeding Episodes
Profilaksa epizod krvavitev
Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on an infection cannot be totally excluded.
Kljub tem ukrepom ni mogoče povsem izključiti prenosa okužbe ob dajanju zdravil, pripravljenih iz človeške krvi ali plazme.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 250 IU
PODATKI NA ZUNANJI OVOJNINI ŠKATLA 250 i.e.
Routine prophylaxis was started with unit doses of 40-50 IU/kg and during the first 6 weeks trough levels of Factor X were measured to adjust the dosage regimen to maintain a trough level of at least 5 IU/dL.
V prvih 6 tednih so merili najnižje ravni faktorja X in skladno s tem prilagajali režim odmerjanja za vzdrževanje najnižje ravni vsaj 5 i.e./dl.
• Immediately invert the vial of solution, which will be drawn into the syringe.
• Takoj obrnite vialo z raztopino, ki jo bo potegnilo v injekcijsko brizgo.
• Separate the empty solvent vial and blue part from the clear part by unscrewing anti-clockwise.
• Odstranite prazno vialo vehikla in modri del s prozornega dela, tako da ju obračate v nasprotni smeri vrtenja urinega kazalca.
Certain anticoagulants including those blocking a blood clotting factor (factor Xa) should not be used in patients with factor X deficiency receiving Coagadex due to a risk of blood clots.
Xa) se pri bolnikih s pomanjkanjem faktorja X, ki prejemajo zdravilo Coagadex, ne sme uporabljati zaradi tveganja za nastanek krvnih strdkov.
- careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, - the testing of each donation and pools of plasma for signs of virus/infections, - the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses.
- vključitev korakov, ki lahko inaktivirajo ali odstranijo viruse, v obdelavo krvi ali plazme.
Frequencies have been evaluated according to the following convention: very common (≥1/10 subjects); common (≥1/100 to <1/10).
(≥1/10 bolnikov); pogosti (≥1/100 do <1/10 bolnikov).
Coagadex to raise plasma factor X levels to 70-90 IU/dL.
v plazmi na 70-90 i.e./dl.
1 solvent vial of 5 mL water for injections
1 pribor za prenos vehikla 1 vialo z vehiklom s 5 ml vode za injekcije
1 solvent vial of 2.5 mL water for injections
1 pribor za prenos vehikla 1 vialo z vehiklom z 2,5 ml vode za injekcije
Coagadex 500 IU powder and solvent for solution for injection human coagulation factor X
Coagadex 500 i.e. prašek in vehikel za raztopino za injiciranje humani koagulacijski faktor X
What you need to know before you use Coagadex 3.
Kaj je zdravilo Coagadex in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Coagadex Kako uporabljati zdravilo Coagadex
Coagadex 250 IU powder and solvent for solution for injection human coagulation factor X
Coagadex 250 i.e. prašek in vehikel za raztopino za injiciranje humani koagulacijski faktor X
In adults and adolescents at least 12 years of age, the expected in vivo peak increase in factor X level expressed as IU/dL (or % of normal) can be estimated using the following formulae:
Pri odraslih in mladostnikih, starih 12 let ali več, je pričakovani največji dvig ravni faktorja X in vivo,
Dose (IU) = body weight (kg) x desired factor X rise (IU/dL or % of normal) x 0.5 OR Increase in factor X level (IU/dL or % of normal) = [total dose (IU)/body weight (kg)] x 2
Odmerek (i.e.) = telesna masa (kg) x želeni dvig faktorja X (i.e./dl ali % običajne vrednosti) x 0,5
The study in young children (see section 5.1) measured incremental recovery at 30 min (IR30min) after the first dose and after the last dose in the study (approximately 6 months later) (see section 5.1) Combining IR30min values for FX:C at the baseline visit (n=9) and the Repeat PK assessment (n=9) gave an overall geometric mean IR of 1.74 (range 1.3-2.2) IU/dL per IU/kg administered (n=9).
V študiji pri mladih otrocih (glejte poglavje 5.1) so merili prirastno zvečanje aktivnosti 30 minut (IR30min) po prvem odmerku in po zadnjem odmerku v študiji (približno 6 mesecev pozneje) (glejte poglavje 5.1).
Infusion site pain
Bolečina na mestu infundiranja
Place the clear end of the transfer device on the powder vial and push straight down until the spike penetrates the rubber stopper and snaps into place.
Položite prozorni konec pribora za prenos vehikla na vialo s praškom in ga potisnite naravnost navzdol, da bo konica prebodla gumijasti zamašek in se zaskočila na svoje mesto.
• Place the blue end of the transfer device on the solvent vial and push straight down until the spike penetrates the rubber stopper and snaps into place.
• Postavite modri konec pribora za prenos vehikla na vialo z vehiklom in ga potisnite naravnost navzdol, da bo konica prebodla gumijasto zaporko in se zaskočila na svoje mesto.
Coagadex 500 IU
Coagadex 500 i.e.
Coagadex 250 IU
coagadex 250 i.e.
coagadex 250 iu
Coagadex 250 i.e.
• tiredness
• utrujenost
• Place the clear end of the transfer device on the powder vial and push straight down until the spike penetrates the rubber stopper and snaps into place.
• Položite prozorni konec pribora za prenos vehikla na vialo s praškom in ga potisnite naravnost navzdol, da bo konica prebodla gumijasto zaporko in se zaskočila na svoje mesto.
How to store Coagadex
Shranjevanje zdravila Coagadex
The following side effects have been reported with Coagadex.
Pri zdravljenju z zdravilom Coagadex so poročali o naslednjih neželenih učinkih.
In a clinical study of Coagadex in subjects with severe or moderate factor X deficiency (basal FX:C <5 IU/dL), the pharmacokinetics of Coagadex were assessed in 16 subjects after administration of a nominal dose of 25 IU/kg.
FX:C < 5 i.e./dl) so ocenjevali farmakokinetiko zdravila Coagadex po dajanju nominalnega odmerka
Dose (IU) = body weight (kg) x desired factor X rise (IU/dL or % of normal) x 0.6 OR Increase in factor X level (IU/dL or % of normal) = [total dose (IU)/body weight (kg)] x 1.7
ALI Dvig ravni faktorja X (i.e./dl ali % običajne vrednosti) = [skupni odmerek (i.e.)/telesna masa (kg)] x 2
Contents of the pack and other information
Shranjevanje zdravila Coagadex Vsebina pakiranja in dodatne informacije
Coagadex 250 IU powder and solvent for solution for injection.
Coagadex 250 i.e. prašek in vehikel za raztopino za injiciranje Coagadex 500 i.e. prašek in vehikel za raztopino za injiciranje
Reconstitution time is less than 2 minutes.
Čas priprave je manj kot 2 minuti.
Date of first authorisation: 23 August 2012 Date of the latest renewal: 24 April 2017
Datum prve odobritve: 23. avgust 2012 Datum zadnjega podaljšanja: 24.april 2017
Resistant (R>)
Rezistentni (R >)
Dry powder: 3 years
Suhi prašek: 3 leta
A risk to the newborns/infants cannot be excluded.
Tveganja za novorojenčka/dojenčka ni možno izključiti.
Calculated using the Cockcroft-Gault formula for adults.
Izračunano z uporabo Cockcroft-Gaultove formule za odrasle.
Renal changes were not reversible but were reduced in severity following a 4 week recovery period.
Ledvične spremembe niso bile reverzibilne, se je pa njihova izrazitost zmanjšala po 4-tedenskem obdobju okrevanja.
The chemical and physical in-use stability has been demonstrated for up to 24 hours at 2-8 °C.
Kemična in fizikalna stabilnost med uporabo sta dokazani do 24 ur pri temperaturi od 2 - 8°C.
In this situation, you should not take medicines that stop or slow bowel movement.
V takšnih okoliščinah ne smete jemati zdravil, ki ustavijo ali upočasnijo gibanje črevesa.
The hospital will dispose of any waste materials safely.
V bolnišnici bodo varno odstranili kakršen koli odpadni material.
Overall, the safety profile in these 227 patients was similar to that observed in the adult population.
V celoti je bil varnostni profil pri teh 227 bolnikih podoben kot so ga zabeležili v odrasli skupini bolnikov.
Frequency categories are derived according to the following conventions: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), not known (cannot be estimated from the available data).
Kategorije pogostnosti so opredeljene po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
• The other ingredient is arginine.
• Druga sestavina zdravila je arginin.
• If you have kidney problems (your doctor may have to prescribe a lower dose)
• če imate težave z ledvicami (zdravnik vam bo morda moral predpisati manjši odmerek),
If the level of your red blood cells fall your doctor may check to see if these antibodies have caused this.
Če bo vrednost rdečih krvnih celic padla, bo vaš zdravnik morda preveril ali so to povzročila ta protitelesa.
The total time interval between starting reconstitution and completing preparation of the intravenous infusion should not exceed 30 minutes.
Celotni čas med začetkom in koncem priprave intravenske infuzije ne sme preseči 30 minut.
Do not use this medicine during pregnancy unless your doctor has told you to.
Tega zdravila ne uporabljajte med nosečnostjo, če vam ne naroči zdravnik.
There is limited experience in treating patients with diabetic foot infections.
Na voljo so le omejene izkušnje pri zdravljenju bolnikov z okužbami diabetičnega stopala.
Carcinogenicity studies have not been conducted.
Študij kancerogenosti niso izvedli.
One or more of these mechanisms may co-exist in a single bacterial isolate.
V istem bakterijskem izolatu lahko soobstaja eden ali več teh mehanizmov.
• Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus)
• Skupina Streptococcus anginosus (vključuje S. anginosus, S. intermedius in S. constellatus)
Gram-negative micro-organisms • Fusobacterium spp.
Gramnegativni mikroorganizmi • Fusobacterium spp.
There was a 33% increase in AUC0-∞ in the elderly that was mainly attributable to age-related changes in renal function.
Pri starejših je bila ugotovljena 33 % večja AUC0-∞; povečanje je bilo predvsem posledica s starostjo povezanih sprememb delovanja ledvic.
≥ 15 to ≤ 30 300 mg ESRD, including haemodialysis
≥ 15 do ≤ 30 300 mg ESRD, vključno s hemodializo
Staphylococcus aureus Streptococcus pneumoniae Streptococcus Groups A, B, C, G
Staphylococcus aureus Streptococcus pneumoniae Streptokoki skupine A, B, C, G
This test looks for certain antibodies which may act against your red blood cells.
Ta preiskava odkriva določena protitelesa, ki lahko delujejo proti rdečim krvnim celicam.
Infusion related reactions (such as phlebitis) can be managed by prolonging the infusion duration.
Z infuzijo povezane reakcije (kot je flebitis) je mogoče obvladati s podaljšanjem časa infundiranja.
Undesirable effects e.g. dizziness may occur and this may have an effect on the ability to drive and use of machines (see section 4.8).
Pojavijo se lahko neželeni učinki, kot je omotica in to lahko vpliva na sposobnost vožnje in upravljanja strojev (glejte poglavje 4.8).
From a microbiological point of view, the medicinal product should be used immediately unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj, razen če sta bila priprava in razredčenje opravljena v nadzorovanih in preverjenih aseptičnih pogojih.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Upoštevati je treba uradne smernice za ustrezno uporabo zdravil za zdravljenje bakterijskih okužb.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8ºC, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
Če ni uporabljeno takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika; čas običajno ne sme presegati 24 ur na temperaturi od 2 do 8 °C, razen če je priprava/redčenje opravljena v nadzorovanih in preverjenih aseptičnih pogojih.
Overall, the adverse events reported in these studies were consistent with the known safety profile for Zinforo.
Na splošno so bili neželeni dogodki, o katerih so poročali v teh študijah, skladni z znanim varnostnim profilom zdravila Zinforo.
Studies have shown that Zinforo solutions for infusion are stable for up to 6 hours at room temperature.
Študije so pokazale, da so raztopine za infundiranje Zinforo na sobni temperaturi stabilne do 6 ur.
Antibacterial activity against other relevant pathogens
Protibakterijska aktivnost proti drugim relevantnim patogenom
• If you have had severe diarrhoea whilst taking antibiotics in the past
• če ste imeli hudo drisko ob jemanju antibiotikov v preteklosti.
The usual recommended dose for children depends on the age and weight of the child and is given every 8 or 12 hours.
Običajen priporočeni odmerek za otroke je odvisen od otrokove starosti in telesne mase ter se uporablja na 8 ali 12 ur.
• If you are allergic to ceftaroline fosamil or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na fosamilceftarolin ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
• Diarrhoea that becomes severe or does not go away or stool that contains blood or mucus during or after treatment with Zinforo.
• driska, ki postane huda ali ne izgine, ali blato, ki vsebuje kri ali sluz, med zdravljenjem z zdravilom Zinforo ali po njem.
When stored as recommended, the product potency is not affected.
Če je zdravilo shranjeno, kot je priporočeno, se njegova moč ne zmanjša.
The powder must be reconstituted with water for injections and the resulting concentrate must then be immediately diluted prior to use.
Prašek je treba pripraviti z vodo za injekcije, tako nastali koncentrat pa redčiti tik pred uporabo.
Adverse reactions are classified according to System Organ Class and frequency.
Neželeni učinki so razvrščeni po organskih sistemih in pogostnosti.
The usual recommended dose for adults is 600 mg every 12 hours.
Običajen priporočeni odmerek za odrasle je 600 mg na 12 ur.
Once the intravenous solution is prepared with diluents listed in section 6.6 it should be administered within 6 hours of preparation.
Ko je intravenska raztopina pripravljena z vehikli, navedenimi v poglavju 6.6, jo je treba aplicirati v 6 urah po pripravi.
After reconstitution: The reconstituted vial should be diluted immediately.
Po rekonstituciji Pripravljeno vialo je treba razredčiti takoj.
120/every 8 hours
120/vsakih 8 ur
* Calculated using the Schwartz formula (in mL/min/1.73 m2) for paediatric patients.
* Izračunano z uporabo Schwartzove formule (v ml/min/1,73 m2) za pediatrične bolnike.
Treatment of overdose should follow standard medical practice;
Pri zdravljenju prevelikega odmerjanja je treba upoštevati standardno medicinsko prakso.
If a severe allergic reaction occurs during treament with Zinforo, the medicinal product should be discontinued and appropriate measures taken.
Če se med zdravljenjem z zdravilom Zinforo pojavi huda alergijska reakcija, je treba uporabo zdravila prekiniti in ustrezno ukrepati.
Juvenile toxicity
Toksičnost pri mladičih
Do not use Zinforo if any of the above applies to you.
Ne uporabljajte zdravila Zinforo, če kaj od naštetega velja za vas.
Relative overdosing could occur in patients with moderate renal impairment.
Relativno preveliko odmerjanje se lahko pojavi pri bolnikih z zmerno okvaro ledvic.
It is free of any particles.
Raztopina je brez delcev.
Therefore, Zinforo should be used with caution in this patient population.
Zato je treba zdravilo Zinforo v tej skupini bolnikov uporabljati previdno.
• More enzymes produced by your liver (as shown in blood tests)
• večje nastajanje encimov v jetrih (to pokažejo preiskave krvi)
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for susceptibility testing are presented below.
Spodaj so prikazane mejne vrednosti za testiranje občutljivosti po EUCAST (European Committee on Antimicrobial Susceptibility Testing).
Infusion volumes for paediatric patients will vary according to the weight of the child.
Volumen infuzije za pediatrične bolnike se razlikuje glede na otrokovo telesno maso.
You may experience fever, flu-like symptoms, sore throat, or any other infection which may be serious.
Pojavijo se vam lahko zvišana telesna temperatura, gripi podobni simptomi, boleče žrelo ali kakšna druga okužba, ki je lahko resna.
The MAH shall perform the pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
The plasma protein binding of ceftaroline is low (approximately 20%) and ceftaroline is not distributed into erythrocytes.
Vezava ceftarolina na beljakovine v plazmi je majhna (približno 20 %) in ceftarolin se ne porazdeli v eritrocite.
• Sudden swelling of your lips, face, throat or tongue; a severe rash; and, swallowing or breathing problems.
• nenadna oteklost ustnic, obraza, žrela ali jezika, hud izpuščaj, težave s požiranjem ali dihanjem.
Patients with pre-existing seizure disorder
Bolniki z obstoječo konvulzivno motnjo
• Redness, pain or swelling where the injection was given.
• pordelost, bolečina ali oteklost na mestu, kjer ste dobili injekcijo
Each vial is for single use only.
Vsaka viala je namenjena samo za enkratno uporabo.
The mean terminal elimination half-life of ceftaroline in healthy adults is approximately 2.5 hours.
Povprečni končni razpolovni čas izločanja ceftarolina je pri zdravih odraslih približno 2,5 ure.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zinforo therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prekinitev/prenehanje zdravljenja z zdravilom Zinforo, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Important: Please refer to the Summary of Product Characteristics before prescribing.
Pomembno: Pred predpisovanjem tega zdravila glejte Povzetek glavnih značilnosti zdravila.
Lab Test
Laboratorijske preiskave
ESRD, including haemodialysis
ESRD, vključno s hemodializo
These may be signs of a severe allergic reaction (anaphylaxis) and may be lifethreatening;
To so lahko znaki hude alergijske reakcije (anafilaksije) in so lahko smrtno nevarni.
Mix gently to reconstitute and check to see that the contents have dissolved completely.
Previdno premešajte, da pripravite raztopino, in se prepričajte, ali se je celotna vsebina povsem raztopila.
Therefore, interactions of ceftaroline with medicinal products that are substrates or inhibitors (e.g. probenecid) of these transporters would not be expected.
Zato ni pričakovati medsebojnih delovanj ceftarolina z zdravili, ki so substrati ali zaviralci (npr. probenecid) teh prenašalcev.
The cysts involved a small portion of the kidney and ocurred in the absence of significant changes in either renal function or urinary parameters.
Ciste so zajele majhen del ledvice in so se pojavile brez pomembnih sprememb delovanja ledvic ali urinskih parametrov.
Other important toxicologic findings noted in the rat and monkey included histopathologic changes in the bladder and spleen.
Med drugimi pomembnimi toksikološkimi izsledki pri podganah in opicah so bile histopatološke spremembe v mehurju in vranici.
ACS Dobfar S.p.A. Nucleo Industriale S. Atto 64100 Teramo Italy
Nucleo Industriale S. Atto 64100 Teramo Italija
Caution is advised when treating such patients.
Pri zdravljenju takšnih bolnikov je potrebna previdnost.
Organisms that express these enzymes and which are therefore resistant to ceftaroline occur at very variable rates between countries and between healthcare facilities within countries.
Stopnja pojavnosti organizmov, ki tvorijo te encime in so zaradi tega odporni na ceftarolin, se spreminja med državami in med zdravstvenimi ustanovami znotraj držav.
If ceftaroline is commenced before susceptibility test results are available then local information on the risk of encountering organisms that express these enzymes should be taken into consideration.
Če ceftarolin uvedemo preden so na voljo rezultati občutljivostnih testov, moramo upoštevati lokalne informacije o verjetnosti prisotnosti organizmov, ki tvorijo te encime.
Animal studies conducted in rat and rabbit do not indicate harmful effects with respect to reproductive toxicity at exposures similar to therapeutic concentrations.
Študije na živalih, izvedene pri podganah in kuncih, ne kažejo škodljivih učinkov glede vpliva na sposobnost razmnoževanja pri izpostavljenosti, podobni kot je pri terapevtskih koncentracijah.
Paediatric population As with adults, the interaction potential is expected to be low in paediatrics.
Tako kot pri odraslih lahko tudi pri pediatrični populaciji pričakujemo majhno možnost za medsebojno delovanje.
What you need to know before you use Zinforo
Kaj morate vedeti, preden boste uporabili zdravilo Zinforo
> 30 to ≤ 50 400 mg c/every 12 hours
> 30 do ≤ 50 400 mg c/vsakih 12 ur
CrCL should be closely monitored and the dose adjusted according to changing renal function.
Očistek kreatinina je treba skrbno spremljati in odmerek prilagoditi glede na spreminjajoče se delovanje ledvic.
Clostridium difficile-associated disease (CDAD) and severe hypersensitivity reactions may also occur.
Lahko se pojavi tudi okužba z bakterijo Clostridium difficile (CDADClostridium difficile-associated disease) in hude preobčutljivostne reakcije.
In such circumstance, the discontinuation of therapy with ceftaroline fosamil and the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered.
V takšnih okoliščinah pride v poštev prenehanje zdravljenja s fosamilceftarolinom in uporaba podpornih ukrepov, obenem z uporabo specifičnega zdravljenja proti Clostridium difficile.